Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Schrödinger Reports Strong First Quarter 2023 Financial Results By: Schrödinger, Inc. via Business Wire May 04, 2023 at 16:00 PM EDT Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1 Study in Healthy Subjects Cash Position Significantly Strengthened by $147.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the first quarter ended March 31, 2023. “We are very pleased with our achievements during the first quarter, which included strong contributions from our software business and our drug discovery collaborations,” stated Ramy Farid, Ph.D., chief executive officer of Schrödinger. “We are making excellent progress across our pipeline of proprietary and collaborative programs. We advanced the first program in our collaboration with BMS to development candidate status, and today reported that we have begun enrollment and dosing in both our ongoing Phase 1 study of SGR-1505 in patients with advanced B cell malignancies and our newly-initiated Phase 1 study in healthy volunteers. The transition to being a clinical-stage company represents a significant milestone for Schrödinger and an important step toward delivering our medicines to patients.” “We delivered a very strong quarter, with software and drug discovery making equal contributions to our revenue result, reflecting our balanced business model. We also made substantial progress in both collaborative and proprietary programs and added capital to our balance sheet, and our partners achieved significant corporate and development milestones further validating our platform,” stated Geoff Porges, MBBS, chief financial officer of Schrödinger. “With our highly differentiated technology, our growing pipeline and our strong cash position, we are well positioned to achieve our goals for 2023 and beyond.” First Quarter 2023 GAAP Financial Results Total revenue for the first quarter increased 33% to $64.8 million, compared to $48.7 million in the first quarter of 2022. Software revenue for the first quarter was $32.2 million, compared to $33.1 million in the first quarter of 2022. Software revenue in the first quarter of 2023 included a small number of multi-year agreements that did not fully offset revenue from multi-year agreements in the first quarter of 2022. Drug discovery revenue was $32.6 million for the first quarter and included a $25 million milestone from BMS, compared to $15.6 million in the first quarter of 2022. Software gross margin increased to 78% for the first quarter, compared to 77% in the first quarter of 2022. Operating expenses were $76.2 million for the first quarter, compared to $56.6 million for the first quarter of 2022. The increase was driven by additional headcount to support the company’s progressing internal pipeline and its software business, CRO expenses, and royalties. Other income for the first quarter was $186.0 million, primarily associated with changes in fair value of equity investments, interest income, and a $147.3 million gain relating to the cash distributions from Nimbus in connection with the sale of Nimbus’s TYK2 inhibitor to Takeda. Other expense for the first quarter of 2022 was $5.8 million driven primarily by changes in the fair value of the company’s equity investments. Net income for the first quarter was $129.1 million, compared to net loss of $34.4 million in the first quarter of 2022. During the first quarter, Schrödinger reported a non-cash tax expense of $26.4 million associated with the cash distribution from Nimbus. At March 31, 2023, Schrödinger had cash, cash equivalents, restricted cash and marketable securities of approximately $532 million, compared to approximately $456 million at December 31, 2022. Three months ended March 31, 2023 2022 % Change (in millions) Total revenue $ 64.8 $ 48.7 33% Software revenue 32.2 33.1 (3%) Drug discovery revenue 32.6 15.6 109% Software gross margin 78 % 77 % Operating expenses $ 76.2 $ 56.6 35% Other income (expense) $ 186.0 $ (5.8 ) – Net income (loss) $ 129.1 $ (34.4 ) – For the three months ended March 31, 2023, Schrödinger reported a non-GAAP net loss of $27.5 million compared to a non-GAAP net loss of $28.3 million for the three months ended March 31, 2022. See “Non-GAAP Information” below and the table at the end of this press release for a reconciliation of non-GAAP net income (loss) to GAAP net income (loss). 2023 Financial Outlook As of May 4, 2023, Schrödinger maintained its financial guidance for the fiscal year ending December 31, 2023: Software revenue growth is expected to be in the range of 13 to 17 percent Drug discovery revenue is expected to range from $70 million to $90 million Software gross margin is expected to be similar to software gross margin for the full year 2022 Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022 and to be similar to revenue growth in 2023 Cash used for operating activities in 2023 is expected to be below cash used for operating activities in 2022 For the second quarter of 2023, software revenue is expected to range from $27 million to $31 million. Recent Highlights Corporate In April, Schrödinger received a $36.0 million distribution, which is the second cash distribution from Nimbus Therapeutics in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor, NDI-034858. Schrödinger received the first distribution of $111.3 million in February 2023 for a total distribution of approximately $147.3 million, all of which was recognized as other income in the company’s first quarter 2023 financial results. NDI-034858 is being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis. In April, Schrödinger published its inaugural corporate sustainability report. The report highlights the company's vision and approach to corporate sustainability, summarizes the company’s 2022 achievements and discloses key data about its corporate sustainability efforts in alignment with GRI and SASB reporting standards. Pipeline Schrödinger continues to advance its MALT1 inhibitor, SGR-1505, in Phase 1 clinical development. A dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and early signals of clinical activity of SGR-1505 as a monotherapy is ongoing in patients with relapsed or refractory B-cell malignancies. Today Schrödinger announced that it has also initiated a Phase 1 study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SGR-1505. Schrödinger is continuing to progress its CDC7 inhibitor, SGR-2921, through IND-enabling studies to support a planned IND submission in the first half of 2023. SGR-2921 has exhibited strong anti-tumor activity as a monotherapy and in combination with standard of care agents in multiple preclinical tumor models. Schrödinger continues to advance its Wee1 inhibitor, SGR-3515, through IND-enabling studies to support a potential IND submission in 2024. Schrödinger continues to advance its multi-target collaboration with BMS and today announced that it received a $25 million milestone payment associated with the advancement of the SOS1/KRAS program to development candidate status. This payment was recognized in drug discovery revenue in the first quarter of 2023. Schrödinger’s collaborator, Morphic Therapeutic, made significant progress advancing MORF-057, an oral α4β7 integrin inhibitor, reporting positive topline results of the EMERALD-1 Phase 2a study in adults with moderate to severe ulcerative colitis (UC). MORF-057 achieved the primary endpoint and demonstrated consistent clinical improvement across other key measures with a favorable tolerability profile. The company continues to progress a pipeline of early-stage wholly-owned programs with potential across a broad range of therapeutic areas. Schrödinger is planning to review its drug discovery programs during its Pipeline Day, a virtual and in-person event that will take place on September 28, 2023. Platform Schrödinger scientists published research showing how the company’s computational methods can be used to refine AlphaFold2 structures for hit discovery. While the publication of the open source AlphaFold protein structure database covers the complete human proteome and represents a significant scientific advance, computational methods are required to adequately refine the AlphaFold structures to improve their utility for drug discovery. Schrödinger scientists published a study describing how FEP+ can be used with homology models for protein thermostability predictions, which can extend Schrödinger’s platform and the use of FEP+ thermostability prediction to targets for which an experimental structure is unavailable. Protein engineering for thermostability has a range of applications, including in the design of antibodies and in chemical industries where protein stability requires optimization to enable enzymes to withstand specific chemical conditions or to extend the shelf-life of protein products. Webcast and Conference Call Information Schrödinger will host a conference call to discuss its first quarter 2023 financial results on Thursday, May 4, 2023, at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. To access the call by phone, please dial 1-888-396-8049 (domestic) or 1-416-764-8646 (international) and refer to conference ID 21402709. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event. Non-GAAP Information Included in this press release is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The company presents non-GAAP net income (loss) and non-GAAP net income (loss) per share, which exclude gains and losses on equity investments, changes in fair value, and non-cash income tax benefits and expenses relating to the company’s gains and losses on equity investments. Adjusting net income to exclude the impact of these items results in a financial presentation for the company without the impact of our equity investments. Management believes non-GAAP net income (loss) and non-GAAP net income (loss) per share are useful measures for investors, taken in conjunction with the company’s GAAP financial statements because they provide greater period-over-period comparability with respect to the company’s operating performance, by excluding non-cash mark-to-market and other valuation adjustments for our equity investments, non-recurring cash distributions from our equity investments and the tax impact of these distributions that are not reflective of the ongoing operating performance of the business. However, the non-GAAP measures should be considered only in addition to, not as a substitute for or as superior to, net income (loss) and net income (loss) per share or other financial measures prepared in accordance with GAAP. Other companies in our industry may calculate non-GAAP net income (loss) and non-GAAP net income (loss) per share, differently than we do, limiting their usefulness as comparative measures. For a reconciliation of non-GAAP net income (loss) and non-GAAP net income (loss) per share to GAAP net income (loss) and GAAP net income (loss) per share, respectively, please refer to the tables at the end of this press release. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs. Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding Schrödinger’s expectations about the speed and capacity of its computational platform, its financial outlook for the fiscal year ending December 31, 2023 and second quarter ending June 30, 2023, its plans to continue to invest in research and its strategic plans to accelerate the growth of its software licensing business and advance its collaborative and proprietary drug discovery programs, the long-term potential of its business, its ability to improve and advance the science underlying its platform, the initiation, timing, progress, and results of its proprietary drug discovery programs and product candidates and the drug discovery programs and product candidates of its collaborators, the clinical potential and favorable properties of its CDC7, MALT1, and Wee1 inhibitors, including SGR-1505, SGR-2921, and SGR-3515, the clinical potential and favorable properties of its collaborators’ product candidates, as well as expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the demand for its software platform, its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, factors adversely affecting the life sciences industry, fluctuations in the value of the U.S. dollar and foreign currencies, its reliance upon its third-party drug discovery collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of IND submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on its business and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023, filed with the Securities and Exchange Commission on May 4, 2023, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share amounts) Three months ended March 31, 2023 2022 Revenues: Software products and services $ 32,213 $ 33,081 Drug discovery 32,569 15,582 Total revenues 64,782 48,663 Cost of revenues: Software products and services 7,115 7,511 Drug discovery 11,974 13,169 Total cost of revenues 19,089 20,680 Gross profit 45,693 27,983 Operating expenses: Research and development 40,741 27,822 Sales and marketing 9,145 6,671 General and administrative 26,308 22,133 Total operating expenses 76,194 56,626 Loss from operations (30,501 ) (28,643 ) Other income (expense): Gain on equity investments 147,322 — Change in fair value 35,737 (6,164 ) Other income 2,937 339 Total other income (expense) 185,996 (5,825 ) Income (loss) before income taxes 155,495 (34,468 ) Income tax expense (benefit) 26,359 (28 ) Net income (loss) 129,136 (34,440 ) Net income (loss) per share of common and limited common stockholders, basic: $ 1.81 $ (0.48 ) Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, basic: 71,467,097 71,050,432 Net income (loss) per share of common and limited common stockholders, diluted: $ 1.75 $ (0.48 ) Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, diluted: 73,818,611 71,050,432 Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except for share and per share amounts) Assets March 31, 2023 December 31, 2022 Current assets: Cash and cash equivalents $ 233,206 $ 90,474 Restricted cash 4,486 5,243 Marketable securities 294,482 360,613 Accounts receivable, net of allowance for doubtful accounts of $125 and $125 46,691 55,953 Unbilled and other receivables, net for allowance for unbilled receivables of $100 and $100 13,473 13,137 Prepaid expenses 11,396 8,569 Total current assets 603,734 533,989 Property and equipment, net 16,493 14,244 Equity investments 101,539 25,683 Goodwill 4,791 4,791 Intangible assets, net — 587 Right of use assets 105,982 105,982 Other assets 6,234 3,311 Total assets $ 838,773 $ 688,587 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable $ 11,987 $ 9,470 Income taxes payable 26,318 355 Accrued payroll, taxes, and benefits 13,152 24,882 Deferred revenue 51,578 57,931 Lease liabilities 11,810 11,006 Other accrued liabilities 8,562 5,166 Total current liabilities 123,407 108,810 Deferred revenue, long-term 20,348 25,598 Lease liabilities, long-term 104,058 105,485 Other liabilities, long-term 700 800 Total liabilities 248,513 240,693 Stockholders' equity: Preferred stock, $$0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively — — Common stock, $$0.01 par value. Authorized 500,000,000 shares; 62,362,015 and 62,163,739 shares issued and outstanding at March 31, 2023 and December 31, 2022 , respectively 623 622 Limited common stock, $$0.01 par value. Authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 92 92 Additional paid-in capital 840,446 828,700 Accumulated deficit (250,002 ) (379,138 ) Accumulated other comprehensive loss (899 ) (2,382 ) Total stockholders' equity of Schrödinger stockholders 590,260 447,894 Total liabilities and stockholders' equity $ 838,773 $ 688,587 Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) Three Months Ended March 31, 2023 2022 Cash flows from operating activities: Net income (loss) $ 129,136 $ (34,440 ) Adjustments to reconcile net income (loss) to net cash used in operating activities: Gain on equity investments (147,322 ) — Fair value adjustments (35,737 ) 6,164 Depreciation and amortization 1,760 969 Stock-based compensation 10,880 9,134 Noncash investment (accretion) amortization (964 ) 1,504 Gain on disposal of property and equipment — (4 ) Decrease (increase) in assets, net of acquisition: Accounts receivable, net 9,262 2,935 Unbilled and other receivables (336 ) (7,390 ) Reduction in the carrying amount of right of use assets — 1,221 Prepaid expenses and other assets (5,750 ) (7,725 ) Increase (decrease) in liabilities, net of acquisition: Accounts payable 2,468 1,328 Income taxes payable 25,963 43 Accrued payroll, taxes, and benefits (11,730 ) (7,454 ) Deferred revenue (11,603 ) (7,079 ) Lease liabilities (623 ) 489 Other accrued liabilities 3,502 594 Net cash used in operating activities (31,094 ) (39,711 ) Cash flows from investing activities: Purchases of property and equipment (3,580 ) (1,696 ) Purchases of equity investments (4,125 ) — Distribution from equity investment 111,329 — Acquisition, net of acquired cash — (6,427 ) Purchases of marketable securities (58,823 ) (55,068 ) Proceeds from maturity of marketable securities 127,401 99,495 Net cash provided by investing activities 172,202 36,304 Cash flows from financing activities: Issuances of common stock upon stock option exercises 867 908 Contribution by noncontrolling interest — — Net cash provided by financing activities 867 908 Net increase (decrease) in cash and cash equivalents and restricted cash 141,975 (2,499 ) Cash and cash equivalents and restricted cash, beginning of period 95,717 123,267 Cash and cash equivalents and restricted cash, end of period $ 237,692 $ 120,768 Supplemental disclosure of cash flow and noncash information Cash paid for income taxes $ 86 $ 37 Supplemental disclosure of non-cash investing and financing activities Purchases of property and equipment in accounts payable 218 317 Purchases of property and equipment in accrued liabilities 86 343 Acquisition of right to use assets, contingency resolution 1,820 1,513 Acquisition of right of use assets — 1,146 Acquisition of lease liabilities — 1,146 Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Ended March 31, 2023 2022 (in thousands, except per share data) Net income (loss) (GAAP) $ 129,136 $ (34,440 ) Income tax expense (benefit) 26,359 — Gain on equity investments (147,322 ) — Change in fair value (35,737 ) 6,164 Non-GAAP net loss $ (27,564 ) $ (28,276 ) Non-GAAP net income (loss) per share of common and limited common stockholders, basic and diluted $ (0.38 ) $ (0.40 ) View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005223/en/Contacts Jaren Irene Madden (Investors) Schrödinger, Inc. jaren.madden@schrodinger.com 617-286-6264 Allie Nicodemo (Media) Schrödinger, Inc. allie.nicodemo@schrodinger.com 617-356-2325 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Schrödinger Reports Strong First Quarter 2023 Financial Results By: Schrödinger, Inc. via Business Wire May 04, 2023 at 16:00 PM EDT Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1 Study in Healthy Subjects Cash Position Significantly Strengthened by $147.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the first quarter ended March 31, 2023. “We are very pleased with our achievements during the first quarter, which included strong contributions from our software business and our drug discovery collaborations,” stated Ramy Farid, Ph.D., chief executive officer of Schrödinger. “We are making excellent progress across our pipeline of proprietary and collaborative programs. We advanced the first program in our collaboration with BMS to development candidate status, and today reported that we have begun enrollment and dosing in both our ongoing Phase 1 study of SGR-1505 in patients with advanced B cell malignancies and our newly-initiated Phase 1 study in healthy volunteers. The transition to being a clinical-stage company represents a significant milestone for Schrödinger and an important step toward delivering our medicines to patients.” “We delivered a very strong quarter, with software and drug discovery making equal contributions to our revenue result, reflecting our balanced business model. We also made substantial progress in both collaborative and proprietary programs and added capital to our balance sheet, and our partners achieved significant corporate and development milestones further validating our platform,” stated Geoff Porges, MBBS, chief financial officer of Schrödinger. “With our highly differentiated technology, our growing pipeline and our strong cash position, we are well positioned to achieve our goals for 2023 and beyond.” First Quarter 2023 GAAP Financial Results Total revenue for the first quarter increased 33% to $64.8 million, compared to $48.7 million in the first quarter of 2022. Software revenue for the first quarter was $32.2 million, compared to $33.1 million in the first quarter of 2022. Software revenue in the first quarter of 2023 included a small number of multi-year agreements that did not fully offset revenue from multi-year agreements in the first quarter of 2022. Drug discovery revenue was $32.6 million for the first quarter and included a $25 million milestone from BMS, compared to $15.6 million in the first quarter of 2022. Software gross margin increased to 78% for the first quarter, compared to 77% in the first quarter of 2022. Operating expenses were $76.2 million for the first quarter, compared to $56.6 million for the first quarter of 2022. The increase was driven by additional headcount to support the company’s progressing internal pipeline and its software business, CRO expenses, and royalties. Other income for the first quarter was $186.0 million, primarily associated with changes in fair value of equity investments, interest income, and a $147.3 million gain relating to the cash distributions from Nimbus in connection with the sale of Nimbus’s TYK2 inhibitor to Takeda. Other expense for the first quarter of 2022 was $5.8 million driven primarily by changes in the fair value of the company’s equity investments. Net income for the first quarter was $129.1 million, compared to net loss of $34.4 million in the first quarter of 2022. During the first quarter, Schrödinger reported a non-cash tax expense of $26.4 million associated with the cash distribution from Nimbus. At March 31, 2023, Schrödinger had cash, cash equivalents, restricted cash and marketable securities of approximately $532 million, compared to approximately $456 million at December 31, 2022. Three months ended March 31, 2023 2022 % Change (in millions) Total revenue $ 64.8 $ 48.7 33% Software revenue 32.2 33.1 (3%) Drug discovery revenue 32.6 15.6 109% Software gross margin 78 % 77 % Operating expenses $ 76.2 $ 56.6 35% Other income (expense) $ 186.0 $ (5.8 ) – Net income (loss) $ 129.1 $ (34.4 ) – For the three months ended March 31, 2023, Schrödinger reported a non-GAAP net loss of $27.5 million compared to a non-GAAP net loss of $28.3 million for the three months ended March 31, 2022. See “Non-GAAP Information” below and the table at the end of this press release for a reconciliation of non-GAAP net income (loss) to GAAP net income (loss). 2023 Financial Outlook As of May 4, 2023, Schrödinger maintained its financial guidance for the fiscal year ending December 31, 2023: Software revenue growth is expected to be in the range of 13 to 17 percent Drug discovery revenue is expected to range from $70 million to $90 million Software gross margin is expected to be similar to software gross margin for the full year 2022 Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022 and to be similar to revenue growth in 2023 Cash used for operating activities in 2023 is expected to be below cash used for operating activities in 2022 For the second quarter of 2023, software revenue is expected to range from $27 million to $31 million. Recent Highlights Corporate In April, Schrödinger received a $36.0 million distribution, which is the second cash distribution from Nimbus Therapeutics in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor, NDI-034858. Schrödinger received the first distribution of $111.3 million in February 2023 for a total distribution of approximately $147.3 million, all of which was recognized as other income in the company’s first quarter 2023 financial results. NDI-034858 is being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis. In April, Schrödinger published its inaugural corporate sustainability report. The report highlights the company's vision and approach to corporate sustainability, summarizes the company’s 2022 achievements and discloses key data about its corporate sustainability efforts in alignment with GRI and SASB reporting standards. Pipeline Schrödinger continues to advance its MALT1 inhibitor, SGR-1505, in Phase 1 clinical development. A dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and early signals of clinical activity of SGR-1505 as a monotherapy is ongoing in patients with relapsed or refractory B-cell malignancies. Today Schrödinger announced that it has also initiated a Phase 1 study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SGR-1505. Schrödinger is continuing to progress its CDC7 inhibitor, SGR-2921, through IND-enabling studies to support a planned IND submission in the first half of 2023. SGR-2921 has exhibited strong anti-tumor activity as a monotherapy and in combination with standard of care agents in multiple preclinical tumor models. Schrödinger continues to advance its Wee1 inhibitor, SGR-3515, through IND-enabling studies to support a potential IND submission in 2024. Schrödinger continues to advance its multi-target collaboration with BMS and today announced that it received a $25 million milestone payment associated with the advancement of the SOS1/KRAS program to development candidate status. This payment was recognized in drug discovery revenue in the first quarter of 2023. Schrödinger’s collaborator, Morphic Therapeutic, made significant progress advancing MORF-057, an oral α4β7 integrin inhibitor, reporting positive topline results of the EMERALD-1 Phase 2a study in adults with moderate to severe ulcerative colitis (UC). MORF-057 achieved the primary endpoint and demonstrated consistent clinical improvement across other key measures with a favorable tolerability profile. The company continues to progress a pipeline of early-stage wholly-owned programs with potential across a broad range of therapeutic areas. Schrödinger is planning to review its drug discovery programs during its Pipeline Day, a virtual and in-person event that will take place on September 28, 2023. Platform Schrödinger scientists published research showing how the company’s computational methods can be used to refine AlphaFold2 structures for hit discovery. While the publication of the open source AlphaFold protein structure database covers the complete human proteome and represents a significant scientific advance, computational methods are required to adequately refine the AlphaFold structures to improve their utility for drug discovery. Schrödinger scientists published a study describing how FEP+ can be used with homology models for protein thermostability predictions, which can extend Schrödinger’s platform and the use of FEP+ thermostability prediction to targets for which an experimental structure is unavailable. Protein engineering for thermostability has a range of applications, including in the design of antibodies and in chemical industries where protein stability requires optimization to enable enzymes to withstand specific chemical conditions or to extend the shelf-life of protein products. Webcast and Conference Call Information Schrödinger will host a conference call to discuss its first quarter 2023 financial results on Thursday, May 4, 2023, at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. To access the call by phone, please dial 1-888-396-8049 (domestic) or 1-416-764-8646 (international) and refer to conference ID 21402709. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event. Non-GAAP Information Included in this press release is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The company presents non-GAAP net income (loss) and non-GAAP net income (loss) per share, which exclude gains and losses on equity investments, changes in fair value, and non-cash income tax benefits and expenses relating to the company’s gains and losses on equity investments. Adjusting net income to exclude the impact of these items results in a financial presentation for the company without the impact of our equity investments. Management believes non-GAAP net income (loss) and non-GAAP net income (loss) per share are useful measures for investors, taken in conjunction with the company’s GAAP financial statements because they provide greater period-over-period comparability with respect to the company’s operating performance, by excluding non-cash mark-to-market and other valuation adjustments for our equity investments, non-recurring cash distributions from our equity investments and the tax impact of these distributions that are not reflective of the ongoing operating performance of the business. However, the non-GAAP measures should be considered only in addition to, not as a substitute for or as superior to, net income (loss) and net income (loss) per share or other financial measures prepared in accordance with GAAP. Other companies in our industry may calculate non-GAAP net income (loss) and non-GAAP net income (loss) per share, differently than we do, limiting their usefulness as comparative measures. For a reconciliation of non-GAAP net income (loss) and non-GAAP net income (loss) per share to GAAP net income (loss) and GAAP net income (loss) per share, respectively, please refer to the tables at the end of this press release. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs. Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding Schrödinger’s expectations about the speed and capacity of its computational platform, its financial outlook for the fiscal year ending December 31, 2023 and second quarter ending June 30, 2023, its plans to continue to invest in research and its strategic plans to accelerate the growth of its software licensing business and advance its collaborative and proprietary drug discovery programs, the long-term potential of its business, its ability to improve and advance the science underlying its platform, the initiation, timing, progress, and results of its proprietary drug discovery programs and product candidates and the drug discovery programs and product candidates of its collaborators, the clinical potential and favorable properties of its CDC7, MALT1, and Wee1 inhibitors, including SGR-1505, SGR-2921, and SGR-3515, the clinical potential and favorable properties of its collaborators’ product candidates, as well as expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the demand for its software platform, its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, factors adversely affecting the life sciences industry, fluctuations in the value of the U.S. dollar and foreign currencies, its reliance upon its third-party drug discovery collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of IND submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on its business and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023, filed with the Securities and Exchange Commission on May 4, 2023, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share amounts) Three months ended March 31, 2023 2022 Revenues: Software products and services $ 32,213 $ 33,081 Drug discovery 32,569 15,582 Total revenues 64,782 48,663 Cost of revenues: Software products and services 7,115 7,511 Drug discovery 11,974 13,169 Total cost of revenues 19,089 20,680 Gross profit 45,693 27,983 Operating expenses: Research and development 40,741 27,822 Sales and marketing 9,145 6,671 General and administrative 26,308 22,133 Total operating expenses 76,194 56,626 Loss from operations (30,501 ) (28,643 ) Other income (expense): Gain on equity investments 147,322 — Change in fair value 35,737 (6,164 ) Other income 2,937 339 Total other income (expense) 185,996 (5,825 ) Income (loss) before income taxes 155,495 (34,468 ) Income tax expense (benefit) 26,359 (28 ) Net income (loss) 129,136 (34,440 ) Net income (loss) per share of common and limited common stockholders, basic: $ 1.81 $ (0.48 ) Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, basic: 71,467,097 71,050,432 Net income (loss) per share of common and limited common stockholders, diluted: $ 1.75 $ (0.48 ) Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, diluted: 73,818,611 71,050,432 Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except for share and per share amounts) Assets March 31, 2023 December 31, 2022 Current assets: Cash and cash equivalents $ 233,206 $ 90,474 Restricted cash 4,486 5,243 Marketable securities 294,482 360,613 Accounts receivable, net of allowance for doubtful accounts of $125 and $125 46,691 55,953 Unbilled and other receivables, net for allowance for unbilled receivables of $100 and $100 13,473 13,137 Prepaid expenses 11,396 8,569 Total current assets 603,734 533,989 Property and equipment, net 16,493 14,244 Equity investments 101,539 25,683 Goodwill 4,791 4,791 Intangible assets, net — 587 Right of use assets 105,982 105,982 Other assets 6,234 3,311 Total assets $ 838,773 $ 688,587 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable $ 11,987 $ 9,470 Income taxes payable 26,318 355 Accrued payroll, taxes, and benefits 13,152 24,882 Deferred revenue 51,578 57,931 Lease liabilities 11,810 11,006 Other accrued liabilities 8,562 5,166 Total current liabilities 123,407 108,810 Deferred revenue, long-term 20,348 25,598 Lease liabilities, long-term 104,058 105,485 Other liabilities, long-term 700 800 Total liabilities 248,513 240,693 Stockholders' equity: Preferred stock, $$0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively — — Common stock, $$0.01 par value. Authorized 500,000,000 shares; 62,362,015 and 62,163,739 shares issued and outstanding at March 31, 2023 and December 31, 2022 , respectively 623 622 Limited common stock, $$0.01 par value. Authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 92 92 Additional paid-in capital 840,446 828,700 Accumulated deficit (250,002 ) (379,138 ) Accumulated other comprehensive loss (899 ) (2,382 ) Total stockholders' equity of Schrödinger stockholders 590,260 447,894 Total liabilities and stockholders' equity $ 838,773 $ 688,587 Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) Three Months Ended March 31, 2023 2022 Cash flows from operating activities: Net income (loss) $ 129,136 $ (34,440 ) Adjustments to reconcile net income (loss) to net cash used in operating activities: Gain on equity investments (147,322 ) — Fair value adjustments (35,737 ) 6,164 Depreciation and amortization 1,760 969 Stock-based compensation 10,880 9,134 Noncash investment (accretion) amortization (964 ) 1,504 Gain on disposal of property and equipment — (4 ) Decrease (increase) in assets, net of acquisition: Accounts receivable, net 9,262 2,935 Unbilled and other receivables (336 ) (7,390 ) Reduction in the carrying amount of right of use assets — 1,221 Prepaid expenses and other assets (5,750 ) (7,725 ) Increase (decrease) in liabilities, net of acquisition: Accounts payable 2,468 1,328 Income taxes payable 25,963 43 Accrued payroll, taxes, and benefits (11,730 ) (7,454 ) Deferred revenue (11,603 ) (7,079 ) Lease liabilities (623 ) 489 Other accrued liabilities 3,502 594 Net cash used in operating activities (31,094 ) (39,711 ) Cash flows from investing activities: Purchases of property and equipment (3,580 ) (1,696 ) Purchases of equity investments (4,125 ) — Distribution from equity investment 111,329 — Acquisition, net of acquired cash — (6,427 ) Purchases of marketable securities (58,823 ) (55,068 ) Proceeds from maturity of marketable securities 127,401 99,495 Net cash provided by investing activities 172,202 36,304 Cash flows from financing activities: Issuances of common stock upon stock option exercises 867 908 Contribution by noncontrolling interest — — Net cash provided by financing activities 867 908 Net increase (decrease) in cash and cash equivalents and restricted cash 141,975 (2,499 ) Cash and cash equivalents and restricted cash, beginning of period 95,717 123,267 Cash and cash equivalents and restricted cash, end of period $ 237,692 $ 120,768 Supplemental disclosure of cash flow and noncash information Cash paid for income taxes $ 86 $ 37 Supplemental disclosure of non-cash investing and financing activities Purchases of property and equipment in accounts payable 218 317 Purchases of property and equipment in accrued liabilities 86 343 Acquisition of right to use assets, contingency resolution 1,820 1,513 Acquisition of right of use assets — 1,146 Acquisition of lease liabilities — 1,146 Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Ended March 31, 2023 2022 (in thousands, except per share data) Net income (loss) (GAAP) $ 129,136 $ (34,440 ) Income tax expense (benefit) 26,359 — Gain on equity investments (147,322 ) — Change in fair value (35,737 ) 6,164 Non-GAAP net loss $ (27,564 ) $ (28,276 ) Non-GAAP net income (loss) per share of common and limited common stockholders, basic and diluted $ (0.38 ) $ (0.40 ) View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005223/en/Contacts Jaren Irene Madden (Investors) Schrödinger, Inc. jaren.madden@schrodinger.com 617-286-6264 Allie Nicodemo (Media) Schrödinger, Inc. allie.nicodemo@schrodinger.com 617-356-2325
Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1 Study in Healthy Subjects Cash Position Significantly Strengthened by $147.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the first quarter ended March 31, 2023. “We are very pleased with our achievements during the first quarter, which included strong contributions from our software business and our drug discovery collaborations,” stated Ramy Farid, Ph.D., chief executive officer of Schrödinger. “We are making excellent progress across our pipeline of proprietary and collaborative programs. We advanced the first program in our collaboration with BMS to development candidate status, and today reported that we have begun enrollment and dosing in both our ongoing Phase 1 study of SGR-1505 in patients with advanced B cell malignancies and our newly-initiated Phase 1 study in healthy volunteers. The transition to being a clinical-stage company represents a significant milestone for Schrödinger and an important step toward delivering our medicines to patients.” “We delivered a very strong quarter, with software and drug discovery making equal contributions to our revenue result, reflecting our balanced business model. We also made substantial progress in both collaborative and proprietary programs and added capital to our balance sheet, and our partners achieved significant corporate and development milestones further validating our platform,” stated Geoff Porges, MBBS, chief financial officer of Schrödinger. “With our highly differentiated technology, our growing pipeline and our strong cash position, we are well positioned to achieve our goals for 2023 and beyond.” First Quarter 2023 GAAP Financial Results Total revenue for the first quarter increased 33% to $64.8 million, compared to $48.7 million in the first quarter of 2022. Software revenue for the first quarter was $32.2 million, compared to $33.1 million in the first quarter of 2022. Software revenue in the first quarter of 2023 included a small number of multi-year agreements that did not fully offset revenue from multi-year agreements in the first quarter of 2022. Drug discovery revenue was $32.6 million for the first quarter and included a $25 million milestone from BMS, compared to $15.6 million in the first quarter of 2022. Software gross margin increased to 78% for the first quarter, compared to 77% in the first quarter of 2022. Operating expenses were $76.2 million for the first quarter, compared to $56.6 million for the first quarter of 2022. The increase was driven by additional headcount to support the company’s progressing internal pipeline and its software business, CRO expenses, and royalties. Other income for the first quarter was $186.0 million, primarily associated with changes in fair value of equity investments, interest income, and a $147.3 million gain relating to the cash distributions from Nimbus in connection with the sale of Nimbus’s TYK2 inhibitor to Takeda. Other expense for the first quarter of 2022 was $5.8 million driven primarily by changes in the fair value of the company’s equity investments. Net income for the first quarter was $129.1 million, compared to net loss of $34.4 million in the first quarter of 2022. During the first quarter, Schrödinger reported a non-cash tax expense of $26.4 million associated with the cash distribution from Nimbus. At March 31, 2023, Schrödinger had cash, cash equivalents, restricted cash and marketable securities of approximately $532 million, compared to approximately $456 million at December 31, 2022. Three months ended March 31, 2023 2022 % Change (in millions) Total revenue $ 64.8 $ 48.7 33% Software revenue 32.2 33.1 (3%) Drug discovery revenue 32.6 15.6 109% Software gross margin 78 % 77 % Operating expenses $ 76.2 $ 56.6 35% Other income (expense) $ 186.0 $ (5.8 ) – Net income (loss) $ 129.1 $ (34.4 ) – For the three months ended March 31, 2023, Schrödinger reported a non-GAAP net loss of $27.5 million compared to a non-GAAP net loss of $28.3 million for the three months ended March 31, 2022. See “Non-GAAP Information” below and the table at the end of this press release for a reconciliation of non-GAAP net income (loss) to GAAP net income (loss). 2023 Financial Outlook As of May 4, 2023, Schrödinger maintained its financial guidance for the fiscal year ending December 31, 2023: Software revenue growth is expected to be in the range of 13 to 17 percent Drug discovery revenue is expected to range from $70 million to $90 million Software gross margin is expected to be similar to software gross margin for the full year 2022 Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022 and to be similar to revenue growth in 2023 Cash used for operating activities in 2023 is expected to be below cash used for operating activities in 2022 For the second quarter of 2023, software revenue is expected to range from $27 million to $31 million. Recent Highlights Corporate In April, Schrödinger received a $36.0 million distribution, which is the second cash distribution from Nimbus Therapeutics in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor, NDI-034858. Schrödinger received the first distribution of $111.3 million in February 2023 for a total distribution of approximately $147.3 million, all of which was recognized as other income in the company’s first quarter 2023 financial results. NDI-034858 is being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis. In April, Schrödinger published its inaugural corporate sustainability report. The report highlights the company's vision and approach to corporate sustainability, summarizes the company’s 2022 achievements and discloses key data about its corporate sustainability efforts in alignment with GRI and SASB reporting standards. Pipeline Schrödinger continues to advance its MALT1 inhibitor, SGR-1505, in Phase 1 clinical development. A dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and early signals of clinical activity of SGR-1505 as a monotherapy is ongoing in patients with relapsed or refractory B-cell malignancies. Today Schrödinger announced that it has also initiated a Phase 1 study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SGR-1505. Schrödinger is continuing to progress its CDC7 inhibitor, SGR-2921, through IND-enabling studies to support a planned IND submission in the first half of 2023. SGR-2921 has exhibited strong anti-tumor activity as a monotherapy and in combination with standard of care agents in multiple preclinical tumor models. Schrödinger continues to advance its Wee1 inhibitor, SGR-3515, through IND-enabling studies to support a potential IND submission in 2024. Schrödinger continues to advance its multi-target collaboration with BMS and today announced that it received a $25 million milestone payment associated with the advancement of the SOS1/KRAS program to development candidate status. This payment was recognized in drug discovery revenue in the first quarter of 2023. Schrödinger’s collaborator, Morphic Therapeutic, made significant progress advancing MORF-057, an oral α4β7 integrin inhibitor, reporting positive topline results of the EMERALD-1 Phase 2a study in adults with moderate to severe ulcerative colitis (UC). MORF-057 achieved the primary endpoint and demonstrated consistent clinical improvement across other key measures with a favorable tolerability profile. The company continues to progress a pipeline of early-stage wholly-owned programs with potential across a broad range of therapeutic areas. Schrödinger is planning to review its drug discovery programs during its Pipeline Day, a virtual and in-person event that will take place on September 28, 2023. Platform Schrödinger scientists published research showing how the company’s computational methods can be used to refine AlphaFold2 structures for hit discovery. While the publication of the open source AlphaFold protein structure database covers the complete human proteome and represents a significant scientific advance, computational methods are required to adequately refine the AlphaFold structures to improve their utility for drug discovery. Schrödinger scientists published a study describing how FEP+ can be used with homology models for protein thermostability predictions, which can extend Schrödinger’s platform and the use of FEP+ thermostability prediction to targets for which an experimental structure is unavailable. Protein engineering for thermostability has a range of applications, including in the design of antibodies and in chemical industries where protein stability requires optimization to enable enzymes to withstand specific chemical conditions or to extend the shelf-life of protein products. Webcast and Conference Call Information Schrödinger will host a conference call to discuss its first quarter 2023 financial results on Thursday, May 4, 2023, at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. To access the call by phone, please dial 1-888-396-8049 (domestic) or 1-416-764-8646 (international) and refer to conference ID 21402709. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event. Non-GAAP Information Included in this press release is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The company presents non-GAAP net income (loss) and non-GAAP net income (loss) per share, which exclude gains and losses on equity investments, changes in fair value, and non-cash income tax benefits and expenses relating to the company’s gains and losses on equity investments. Adjusting net income to exclude the impact of these items results in a financial presentation for the company without the impact of our equity investments. Management believes non-GAAP net income (loss) and non-GAAP net income (loss) per share are useful measures for investors, taken in conjunction with the company’s GAAP financial statements because they provide greater period-over-period comparability with respect to the company’s operating performance, by excluding non-cash mark-to-market and other valuation adjustments for our equity investments, non-recurring cash distributions from our equity investments and the tax impact of these distributions that are not reflective of the ongoing operating performance of the business. However, the non-GAAP measures should be considered only in addition to, not as a substitute for or as superior to, net income (loss) and net income (loss) per share or other financial measures prepared in accordance with GAAP. Other companies in our industry may calculate non-GAAP net income (loss) and non-GAAP net income (loss) per share, differently than we do, limiting their usefulness as comparative measures. For a reconciliation of non-GAAP net income (loss) and non-GAAP net income (loss) per share to GAAP net income (loss) and GAAP net income (loss) per share, respectively, please refer to the tables at the end of this press release. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs. Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding Schrödinger’s expectations about the speed and capacity of its computational platform, its financial outlook for the fiscal year ending December 31, 2023 and second quarter ending June 30, 2023, its plans to continue to invest in research and its strategic plans to accelerate the growth of its software licensing business and advance its collaborative and proprietary drug discovery programs, the long-term potential of its business, its ability to improve and advance the science underlying its platform, the initiation, timing, progress, and results of its proprietary drug discovery programs and product candidates and the drug discovery programs and product candidates of its collaborators, the clinical potential and favorable properties of its CDC7, MALT1, and Wee1 inhibitors, including SGR-1505, SGR-2921, and SGR-3515, the clinical potential and favorable properties of its collaborators’ product candidates, as well as expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the demand for its software platform, its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, factors adversely affecting the life sciences industry, fluctuations in the value of the U.S. dollar and foreign currencies, its reliance upon its third-party drug discovery collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of IND submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on its business and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023, filed with the Securities and Exchange Commission on May 4, 2023, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share amounts) Three months ended March 31, 2023 2022 Revenues: Software products and services $ 32,213 $ 33,081 Drug discovery 32,569 15,582 Total revenues 64,782 48,663 Cost of revenues: Software products and services 7,115 7,511 Drug discovery 11,974 13,169 Total cost of revenues 19,089 20,680 Gross profit 45,693 27,983 Operating expenses: Research and development 40,741 27,822 Sales and marketing 9,145 6,671 General and administrative 26,308 22,133 Total operating expenses 76,194 56,626 Loss from operations (30,501 ) (28,643 ) Other income (expense): Gain on equity investments 147,322 — Change in fair value 35,737 (6,164 ) Other income 2,937 339 Total other income (expense) 185,996 (5,825 ) Income (loss) before income taxes 155,495 (34,468 ) Income tax expense (benefit) 26,359 (28 ) Net income (loss) 129,136 (34,440 ) Net income (loss) per share of common and limited common stockholders, basic: $ 1.81 $ (0.48 ) Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, basic: 71,467,097 71,050,432 Net income (loss) per share of common and limited common stockholders, diluted: $ 1.75 $ (0.48 ) Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, diluted: 73,818,611 71,050,432 Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except for share and per share amounts) Assets March 31, 2023 December 31, 2022 Current assets: Cash and cash equivalents $ 233,206 $ 90,474 Restricted cash 4,486 5,243 Marketable securities 294,482 360,613 Accounts receivable, net of allowance for doubtful accounts of $125 and $125 46,691 55,953 Unbilled and other receivables, net for allowance for unbilled receivables of $100 and $100 13,473 13,137 Prepaid expenses 11,396 8,569 Total current assets 603,734 533,989 Property and equipment, net 16,493 14,244 Equity investments 101,539 25,683 Goodwill 4,791 4,791 Intangible assets, net — 587 Right of use assets 105,982 105,982 Other assets 6,234 3,311 Total assets $ 838,773 $ 688,587 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable $ 11,987 $ 9,470 Income taxes payable 26,318 355 Accrued payroll, taxes, and benefits 13,152 24,882 Deferred revenue 51,578 57,931 Lease liabilities 11,810 11,006 Other accrued liabilities 8,562 5,166 Total current liabilities 123,407 108,810 Deferred revenue, long-term 20,348 25,598 Lease liabilities, long-term 104,058 105,485 Other liabilities, long-term 700 800 Total liabilities 248,513 240,693 Stockholders' equity: Preferred stock, $$0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively — — Common stock, $$0.01 par value. Authorized 500,000,000 shares; 62,362,015 and 62,163,739 shares issued and outstanding at March 31, 2023 and December 31, 2022 , respectively 623 622 Limited common stock, $$0.01 par value. Authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 92 92 Additional paid-in capital 840,446 828,700 Accumulated deficit (250,002 ) (379,138 ) Accumulated other comprehensive loss (899 ) (2,382 ) Total stockholders' equity of Schrödinger stockholders 590,260 447,894 Total liabilities and stockholders' equity $ 838,773 $ 688,587 Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) Three Months Ended March 31, 2023 2022 Cash flows from operating activities: Net income (loss) $ 129,136 $ (34,440 ) Adjustments to reconcile net income (loss) to net cash used in operating activities: Gain on equity investments (147,322 ) — Fair value adjustments (35,737 ) 6,164 Depreciation and amortization 1,760 969 Stock-based compensation 10,880 9,134 Noncash investment (accretion) amortization (964 ) 1,504 Gain on disposal of property and equipment — (4 ) Decrease (increase) in assets, net of acquisition: Accounts receivable, net 9,262 2,935 Unbilled and other receivables (336 ) (7,390 ) Reduction in the carrying amount of right of use assets — 1,221 Prepaid expenses and other assets (5,750 ) (7,725 ) Increase (decrease) in liabilities, net of acquisition: Accounts payable 2,468 1,328 Income taxes payable 25,963 43 Accrued payroll, taxes, and benefits (11,730 ) (7,454 ) Deferred revenue (11,603 ) (7,079 ) Lease liabilities (623 ) 489 Other accrued liabilities 3,502 594 Net cash used in operating activities (31,094 ) (39,711 ) Cash flows from investing activities: Purchases of property and equipment (3,580 ) (1,696 ) Purchases of equity investments (4,125 ) — Distribution from equity investment 111,329 — Acquisition, net of acquired cash — (6,427 ) Purchases of marketable securities (58,823 ) (55,068 ) Proceeds from maturity of marketable securities 127,401 99,495 Net cash provided by investing activities 172,202 36,304 Cash flows from financing activities: Issuances of common stock upon stock option exercises 867 908 Contribution by noncontrolling interest — — Net cash provided by financing activities 867 908 Net increase (decrease) in cash and cash equivalents and restricted cash 141,975 (2,499 ) Cash and cash equivalents and restricted cash, beginning of period 95,717 123,267 Cash and cash equivalents and restricted cash, end of period $ 237,692 $ 120,768 Supplemental disclosure of cash flow and noncash information Cash paid for income taxes $ 86 $ 37 Supplemental disclosure of non-cash investing and financing activities Purchases of property and equipment in accounts payable 218 317 Purchases of property and equipment in accrued liabilities 86 343 Acquisition of right to use assets, contingency resolution 1,820 1,513 Acquisition of right of use assets — 1,146 Acquisition of lease liabilities — 1,146 Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Ended March 31, 2023 2022 (in thousands, except per share data) Net income (loss) (GAAP) $ 129,136 $ (34,440 ) Income tax expense (benefit) 26,359 — Gain on equity investments (147,322 ) — Change in fair value (35,737 ) 6,164 Non-GAAP net loss $ (27,564 ) $ (28,276 ) Non-GAAP net income (loss) per share of common and limited common stockholders, basic and diluted $ (0.38 ) $ (0.40 ) View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005223/en/
Jaren Irene Madden (Investors) Schrödinger, Inc. jaren.madden@schrodinger.com 617-286-6264 Allie Nicodemo (Media) Schrödinger, Inc. allie.nicodemo@schrodinger.com 617-356-2325
